Format

Send to:

Choose Destination
See comment in PubMed Commons below
BJU Int. 2014 May;113(5b):E106-11. doi: 10.1111/bju.12422. Epub 2014 Jan 17.

A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.

Author information

  • 1Yale University School of Medicine, Department of Urology, New Haven, CT, USA; Yale University, Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER), New Haven, CT, USA.

Abstract

OBJECTIVE:

To assess recommendations for prostate-specific antigen (PSA) screening in a national survey of radiation oncologists and urologists following the recent USA Preventive Services Task Force (USPSTF) grade D recommendation.

METHODS:

A random sample of 1366 radiation oncologists and urologists were identified from the American Medical Association Physician Masterfile. From November 2011 to April 2012, a mail survey was sent to query PSA screening recommendations for men at average risk of prostate cancer for the following age groups: 40-49, 50-59, 60-69, 70-74, 75-79 and ≥80 years. Multivariable logistic regression was used to test for differences in PSA-based screening recommendations by physician characteristics.

RESULTS:

Response rates were similar at 52% for radiation oncologists and urologists (P = 0.92). Overall, 51.5% of respondents recommended PSA-based screening for men aged 40-49 years, while nearly all endorsed it for those aged 50-74 years (96.1% for 50-59, 97.3% for 60-69, and 87.7% for 70-74 years). However, screening recommendations decreased to 43.9% and 12.8% for men aged 75-79 and ≥80 years, respectively. On multivariable analysis, urologists were more likely to recommend screening for men aged 40-49 (odds ratio [OR] 3.09; P < 0.001) and 50-59 years (OR 3.81; P = 0.01), but less likely for men aged 75-79 (OR 0.66; P = 0.01) and ≥80 years (OR 0.45; P = 0.002) compared with radiation oncologists.

CONCLUSION:

While radiation oncologists and urologists recommended PSA screening for men aged 50-69 years, there was less agreement about screening for younger (40-49 years old) and older (≥70 years) men at average risk for prostate cancer.

© 2013 The Authors. BJU International © 2013 BJU International.

KEYWORDS:

outcomes; prostate cancer; prostate-specific antigen; screening; survey

PMID:
24053213
[PubMed - indexed for MEDLINE]
PMCID:
PMC4353641
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk